文献速递肝病消化道肿瘤与早癌

Galectin-14通过驱动硫酸乙酰肝素修饰损害肝细胞癌抗肿瘤免疫

Galectin-14, a primate-specific oncofetal protein, impairs anti-tumour immunity in hepatocellular carcinoma by driving elevated heparan sulphate modification.
PubMed 文献 · Gut · 2026-07-28

该研究探讨硫酸乙酰肝素(HS)修饰在肝细胞癌(HCC)进展中的作用及调控机制。研究发现HS升高与HCC患者不良生存和T细胞耗竭相关,灵长类特异性癌胚蛋白galectin-14是HS合成的上游调控因子,通过结合UGP2促进UDP糖基供体产生,驱动HS修饰和CD8+ T细胞耗竭,促进HCC免疫逃逸。

要点

  • HS修饰升高与HCC患者不良生存及T细胞耗竭相关
  • Galectin-14是HS合成的上游调控因子,促进HCC进展和免疫逃逸
  • Galectin-14直接结合UGP2,促进其寡聚化和酶活性,增加HS合成

核心结论

  • Galectin-14是HCC免疫抑制的关键癌胚调控因子,通过重编程UGP2介导的糖基供体产生促进HS修饰和T细胞功能障碍,可作为潜在诊断标志物和治疗靶点。

研究设计与样本

  • 通过HCC临床数据和体内模型分析HS与不良预后及免疫功能障碍的关联。
  • 利用外源性HS或HS耗竭在体内外验证T细胞功能。
  • 对HS高/低肿瘤克隆进行转录组筛选鉴定HS上游调控因子。
  • 通过体外遗传操作和转基因小鼠功能确认galectin-14。
  • 通过代谢和蛋白相互作用研究揭示galectin-14驱动UDP糖基供体产生和HS合成的机制。

主要发现

  • HS修饰升高与HCC患者不良生存相关,并与T细胞耗竭相关。
  • Galectin-14被鉴定为HS合成的上游调控因子,促进HCC进展和免疫逃逸。
  • Galectin-14通过诱导接触依赖性CD8+ T细胞耗竭发挥作用,部分由T细胞上的FGFR1信号介导。
  • Galectin-14重编程糖代谢,促进HS链所需的UDP糖基供体(UDP-Glc、UDP-GlcNAc、UDP-GlcA)合成。
  • Galectin-14直接结合UGP2,促进其寡聚化和酶活性,从而促进HS产生。

临床怎么用

  • Galectin-14和HS修饰可作为HCC潜在的诊断标志物。
  • 靶向galectin-14-UGP2-HS轴可能成为HCC免疫治疗的新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The liver naturally exhibits robust glycosylation processes, yet how aberrant glycosylation affects hepatocellular carcinoma (HCC) and its underlying mechanisms remains poorly understood. OBJECTIVE: To investigate the role of heparan sulphate (HS) modification in HCC progression and identify its underlying regulatory mechanism. DESIGN: The association of HS with poor prognosis and immune dysfunction was analysed through HCC clinical data and in vivo models. T cell functions were validated in vivo and in vitro via exogenous HS or HS depletion. Transcriptomic screening of HS-high and HS-low tumour clones was performed to identify upstream regulators of HS. Candidate galectin-14 was functionally confirmed through genetic manipulation in vitro and in transgenic mice. Metabolic and protein-interaction studies showed how galectin-14 drives UDP-glycosyl donor production and HS synthesis. RESULTS: Elevated HS modification correlated with poor survival and was linked to T cell exhaustion in patients with HCC. The primate-specific oncofetal protein galectin-14 was identified as an upstream regulator of HS synthesis. Galectin-14 promoted HCC progression and immune evasion by inducing contact-dependent CD8+ T cell exhaustion, partly mediated by FGFR1 signalling on T cells. It reprogrammed glycometabolism to boost synthesis of UDP-glycosyl donors (UDP-Glc, UDP-GlcNAc, UDP-GlcA) required for HS chains. Mechanistically, galectin-14 directly bound UDP-glucose pyrophosphorylase 2 (UGP2), facilitating its oligomerisation and enzymatic activity, thereby fueling HS production. CONCLUSION: This study defines galectin-14 as a key oncofetal regulator of HCC immunosuppression by rewiring UGP2-mediated glycosyl donor production to promote elevated HS modification and T cell dysfunction, highlighting a potential diagnostic marker and promising therapeutic avenue in HCC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Yang G, Gou L, Liu X, et al. Galectin-14, a primate-specific oncofetal protein, impairs anti-tumour immunity in hepatocellular carcinoma by driving elevated heparan sulphate modification. Gut. 2026. PMID: 42521487. doi:10.1136/gutjnl-2026-338068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。